IL1RL1 gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids
Dijk, F N; Vijverberg, S J; Hernandez-Pacheco, N; Repnik, K; Karimi, L; Mitratza, M; Farzan, N; Nawijn, M C; Burchard, E G; Engelkes, M

Published in:
Allergy

DOI:
10.1111/all.14125

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
IL1RL1 gene variations are associated with asthma exacerbations in children and adolescents using inhaled corticosteroids


* These authors contributed equally.
Asthma, one of the most common chronic diseases in childhood, is caused by interactions between genes and environmental factors. The mainstay of treatment is daily use of inhaled corticosteroids (ICS), which are the most effective medication for controlling asthma symptoms and preventing (severe) exacerbations. ICS use reduces both hospitalizations and mortality rates\(^1\) and improves asthma control; reflected in forced expiratory volume in 1 second (FEV\(_1\)) levels and fraction of exhaled nitric oxide (FeNO). These effects are particularly observed in asthma patients with eosinophilic, type 2 airway inflammation.\(^2\) However, responses to ICS are heterogeneous, which while controversial, possibly reflect genetic associations.\(^4\)

Genome Wide Association studies (GWAS) have reproducibly found the *Interleukin 1 receptor like 1* (*IL1RL1, ST2*) gene to be associated with asthma susceptibility.\(^5\) *IL1RL1* single nucleotide polymorphisms (SNPs) and *IL1RL1* expression levels have been associated with blood eosinophils and markers of Th2 type inflammation.\(^6,7\) However, the influence of *IL1RL1* SNPs on the effectiveness of asthma treatment has not been investigated. Since the IL-33/IL1RL1 pathway has been associated with eosinophilic, type 2, inflammation, we hypothesized that *IL1RL1* SNPs may affect corticosteroid treatment response in asthma patients. Since *IL1RL1*-a functions as a decoy receptor to dampen IL-33 induced signaling, genetically determined low levels of IL1RL1-a may predispose to enhanced IL-33 induced inflammation with consequently more exacerbations.

In the current study, we investigated whether *IL1RL1* gene variants are associated with asthma exacerbations (based on ER visits/hospitalizations and courses of oral corticosteroid (OCS) use), questionnaire-based asthma control and FeNO levels in asthma patients using ICS. Furthermore, we aimed to identify whether there is a pharmacogenetic effect of *IL1RL1* variants on change in FeNO levels and FEV\(_1\)% predicted in asthma patients after 4-6 weeks of ICS treatment.

After close inspection of the Linkage Disequilibrium structure of *IL1RL1*, we selected 6 *IL1RL1* SNPs that tag important LD blocks in *IL1RL1* \((r^2 > 0.8)\) with SNPs previously found to be associated with asthma;\(^5\) rs13431828, rs1041973, rs1420101, rs1946131, rs1921622 and rs10204137 (Table S1). Cross-sectional *IL1RL1* SNP discovery analysis was performed in ICS treated asthmatic children, mainly of European ancestry, from the Pharmacogenetics of Asthma Medication in Children: Medication with Anti-inflammatory effects (PACMAN) cohort (N=820) using logistic and linear regression models. We replicated FDR corrected significant findings (P < 0.05) in four different cohorts collaborating within the Pharmacogenomics in Childhood Asthma
(PiCA) consortium, one Hispanic/Latino study; Genes-Environment and Admixture in Latino Americans (GALA II, N=876) study, one African American population; Study of African Americans, Asthma, Genes, and Environments (SAGE, N=525), and two European studies (≥96% European ancestry); the Effectiveness and Safety of Treatment with Asthma Therapy in children (ESTATe, N=197) and SLOVENIA (N=104). In addition, we performed a meta-analysis (N= 2,412). The longitudinal effect of IL1RL1 on FeNO levels and FEV1% predicted upon ICS treatment in asthmatic children and adults was assessed in the SLOVENIA cohort. Conditional analysis was performed in PACMAN to assess the independent effects of the IL1RL1 SNPs.

A detailed representation of the included cohorts and the allele frequencies of the IL1RL1 SNPs is provided in Table S2 and Table S3. In PACMAN, we found a significant association between 4 of the 6 SNPs (rs13431828, rs1420101, rs1921622 and rs10204137) with ER visits and ‘any exacerbation’ (Table 1A-C), which were selected for the replication study. Sensitivity analyses on Dutch ethnicity, atopy and medication adherence did not change these results. We did not observe an association with questionnaire-based asthma control or FeNO measurements (Table S4A-B).

In GALA II, we replicated our findings with significant results with the same direction of effect for rs13431828, rs1420101, rs1921622 on ER visits/hospitalizations and ‘any exacerbation’. Rs10204137 showed a significant association with ‘any exacerbation’ (Table 1A-C). In SAGE, rs1921622 was associated with ‘any exacerbation’ but the direction of the effect differed when compared to PACMAN. No association between IL1RL1 and questionnaire-based asthma control was found. In the smaller SLOVENIA and ESTATe studies no significant cross-sectional or longitudinal associations were found (Table S5).

Meta-analysis of the 4 IL1RL1 SNPs carried through to replication showed statistically significant results for rs13431828. The C allele of rs13431828 was associated with ER visits/hospitalizations (OR=1.32, P=0.02) and increased risk of ‘any exacerbations’ (1.31, P=0.02) (Table 1A-C, Fig. 1). No evidence of heterogeneity was found (Q=3.6, P=0.33).

Conditional analysis in PACMAN on rs13431828, rs1420101, rs1921622 and rs10204137 for ‘any exacerbation’ indicated that rs13431828 was the most independently associated SNP (Table S6).

These results provide new evidence that children and adolescents with the IL1RL1 risk alleles are prone to more exacerbations than children with the protective genotypes, while using ICS. This extends previous findings that SNPs in IL1RL1 are important in different asthma phenotypes, with more prominent effect in studies investigating childhood onset asthma. Rs1420101 has been
specifically linked to the type 2-high asthma phenotype, as well as to increased eosinophil numbers in peripheral blood.

We observed replicable associations of the same IL1RL1 risk alleles in the Caucasian (PACMAN) and Hispanic/Latino (GALA II) population, but not in the African American study population (SAGE). This could be due to differences in ethnicity between study groups and LD patterns in this gene, suggested by the observed differences in allele frequency between the cohorts (see Table S3). It is possible that our results may have been influenced by factors other than currently included in the model such as inhalation technique or respiratory infections, but as such data was not available in all cohorts these were not considered.

Different mechanisms may explain our findings. Firstly, IL1RL1 SNPs may modify the asthma phenotype into a more severe phenotype, with more severe exacerbations, which are insufficiently treated with the ICS dosages prescribed to the children in this study. The risk alleles described in our study for rs13431828 (C), rs1420101 (T), rs1921622 (A) and rs10204137 (A) were previously associated with lower IL1RL1 blood methylation levels and lower serum IL1RL1-a levels, indicating that the associated SNPs are important for regulation of IL1RL1 expression. Another mechanism to explain our results is that IL1RL1 may have a direct pharmacogenetic interaction with steroids resulting in reduced efficacy of the steroids. Rs10204137 is a missense mutation and has been associated with increased IL1RL1-a expression, which induces IL-33 expression and enhances IL-33 responsiveness. Moreover, rs10204137 tags an LD block that contains 5 nonsynonymous coding SNPs that result in changes to four amino acids in the intracellular domain of IL1RL1-b. These coding changes affect the Toll/interleukin-1 receptor (TIR) domain of the intracellular part of the IL1RL1 protein, which plays an important role in IL-33 induced signal transduction by IL1RL1. This triggers a signaling cascade that eventually results in the activation of downstream mitogen-activated protein kinases and transcription factors, such as nuclear factor kB (NF-kB) and activator protein-1. Through this pathway, asthmatic children carrying the risk allele of rs10204137 may be more sensitive to IL-33. As IL1RL1 is expressed on effector cells of the type-2 immune response such as mast cells, eosinophils, basophils, Th2 cells and ILC2 cells, an increased sensitivity to IL33 will contribute to an exaggerated type-2 inflammatory response after viral or allergen exposure.

Secondly, IL1RL1 may have a direct pharmacogenetic interaction with steroids resulting in reduced efficacy of the steroids. A recent study on ulcerative colitis found an association between dexamethasone and upregulation of soluble IL1RL1 transcription mediated via interaction of the steroid with the glucocorticoid-responsive element in the IL1RL1 promoter patients carrying polymorphisms. To gain more insight into the mechanism underlying our finding future studies...
should be performed in larger cohorts or with the use of biobank data. This study shows that an $IL1RL1$ SNP effect is present in asthmatic children using ICS. This highlights the potential investigating if novel treatment strategies targeting the IL33/IL1RL1 pathway could be used as add-on asthma treatment in patients using ICS.
References


Authors and institutional affiliations:

F.N. Dijk,¹ S.J. Vijverberg,²,³ N. Hernandez-Pacheco,⁴,⁵ K. Repnik,⁶,⁷ L. Karimi,⁸ M. Mitratza,⁹ N. Farzan,²,³ M.C. Nawijn,¹⁰ E.G. Burchard,¹¹,¹² M. Engelkes,⁸ K. M. Verhamme,⁸ U. Potočnik,⁶,⁷ M. Pino-Yanes,⁴,⁵,¹³ D.S. Postma,¹⁴ A. Maitland-van der Zee,²,³,¹⁵* and G.H. Koppelman¹*

¹Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
²Department of Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, P.O. Box 22700, NL-1100 DE Amsterdam, The Netherlands.
³Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University, The Netherlands.
⁴Research Unit, Hospital Universitario N.S. de Candelaria, Universidad de La Laguna, Santa Cruz de Tenerife, Spain.
⁵Genomics and Health Group, Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, La Laguna, Tenerife, Spain.
⁶Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
⁷Laboratory for Biochemistry, Molecular Biology and Genomics, Faculty for Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia.
⁸Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁹Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University, the Netherlands.
¹⁰Laboratory of Allergology and Pulmonary Diseases, Pathology and Medical Biology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
¹¹Department of Medicine, University of California, San Francisco, CA, United States.
¹²Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, United States.
¹³CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
¹⁴Department of Pulmonary Diseases, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Pediatric Respiratory Medicine and Allergy, Emma’s Children Hospital, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands.

* These authors contributed equally.

Address of correspondence:
Gerard H. Koppelman, MD, PhD
Pediatric Pulmonology and Pediatric Allergology
Beatrix Children’s Hospital
University Medical Center Groningen
PO Box 30.001
9700 RB Groningen, the Netherlands
Phone: + 31 50 3614213
Fax: + 31 50 3614235
E-mail: g.h.koppelman@umcg.nl

Acknowledgments:
We would like to thank the participants and their parents of the studied cohorts for their participation. We also would like to acknowledge the field workers, data managers and scientific collaborators dedicated to these cohorts.

The authors acknowledge the GALA II and SAGE investigators (Kelley Meade, Harold J. Farber, Pedro C. Avila, Denise Serebrisky, Shannon M. Thyne, Emerita Brigino-Buenaventura, William Rodriguez-Cintron, Saunak Sen, Rajesh Kumar, Michael Lenoir, Luisa N. Borrell, and Jose R. Rodriguez-Santana), the recruiters, participants and the study coordinator Sandra Salazar. We thank as well the ESTAte investigators (Pharmo: Ron Herings, Annemarie Janse, Jettie Overbeek, Josine Kuiper. IPCI: Katia Verhamme, Hettie Janssens, Johan de Jongste, Miriam Sturkenboom).

Author contributions:
FND, SJV, AM and GHK were involved in the conception and design of the study. FND, SJV, NH, KR, LK, MM, ME participated in data collection and performed the analysis. FND, SJV, AM and GHK contributed to the interpretation of the data. FND and GHK drafted the manuscript for important intellectual content. All authors discussed the results and commented on the manuscript.
Conflict of Interest Statement:
N. Hernandez-Pacheco received a grant from Instituto de Salud Carlos III (ISCIII) and was co-funded by the European Social Funds from the European Union (ESF) “ESF invests in your future”. M.C. Nawijn received a grant from GSK during the conduct of this study and outside the submitted work. M.E. Engelkes received a grant from Zonmw. K. M. Verhamme received a grant from ZonMw and she works for a research group who in the past received unconditional grants from: Yamanouchi, Pfizer/Boehringer Ingelheim, Novartis and GSK. M Pino-Yanes received a grant from the Spanish Ministry of Economy, Industry and Competitiveness and a grant from Instituto de Salud Carlos III (ISCIII). A.H. Maitland-van der Zee received an unrestricted research grant from GSK, and Boehringer Ingelheim. She also received a grant from ERANET ERACOSYSMED, and she participated in an advisory board for AstraZeneca. D.S. Postma declares that the University of Groningen has received money for D.S. Postma regarding a grant for research from AstraZeneca, Chiesi, Genentech, GSK and Roche. Fees for consultancies were given to the University of Groningen by AstraZeneca, Chiesi, and GSK. G.H. Koppelman received grants from the Lung Foundation of the Netherlands, the Ubbo Emmius Foundation, during the conduct of the study; and he received grants from Lung Foundation of the Netherlands, GSK, Tetri Foundation, Vertex, TEVA the Netherlands, outside the submitted work. GHK participated in an advisory board meeting of GSK. The rest of the authors declare that they have no relevant conflict of interests.

Funding information:
The PACMAN study was supported by an unrestricted grant from GlaxoSmithKline (GSK), whereas genetic analysis for the present study was supported by a Lung Foundation of the Netherlands grant no. AF3.2.09.081JU. FND was supported by the Ubbo Emmius Foundation. The GALA II and SAGE studies were funded by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, National Institutes of Health (1R01HL117004, R01HL128439, R01HL135156, and 1X01HL134589), National Institute of Health and Environmental Health Sciences (R01ES015794 and R21ES24844), the National Institute on Minority Health and Health Disparities (1P60MD006902, U54MD009523, and 1R01MD010443), and the Tobacco-Related Disease Research Program under Award Number 24RT-0025 to EGB. This work was also funded by Instituto de Salud Carlos III (AC15/00015, PI14/00844), co-financed by the European Regional Development Funds, “A way of making Europe”. NH-P was funded by a fellowship (FI16/00136) from Instituto de Salud Carlos III (ISCIII) and co-funded by
the European Social Funds from the European Union (ESF) “ESF invests in your future” and MP-
Y was supported by the Ramón y Cajal Program (RYC-2015-17205) by the Spanish Ministry of
Economy, Industry, and Competitiveness. For the SLOVENIA study, the authors acknowledge the
financial support from the Slovenian Research Agency (research core funding No. P3-0067) and
from SysPharmPedia grant, co-financed by Ministry of Education, Science and Sport of the
Republic of Slovenia. The ESTATe project was supported by a ZonMw Grant No 113201006. The
PiCA study was overall supported by ERACoSysMed 1st Joint Transnational Call
(SysPharmPedia).
# Tables

## TABLE 1. Results of associations of IL1RL1 SNPs with ER visits/hospitalizations, OCS use and ‘any exacerbation per study and meta-analysis.

<table>
<thead>
<tr>
<th></th>
<th>ER visits/hospitalisations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PACMAN (n=698)</td>
</tr>
<tr>
<td></td>
<td>OR (95% CI)</td>
</tr>
<tr>
<td></td>
<td>P</td>
</tr>
<tr>
<td>rs13431828</td>
<td>T/C</td>
</tr>
<tr>
<td></td>
<td>2.78 (1.11-6.94)</td>
</tr>
<tr>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>rs1041973</td>
<td>A/C</td>
</tr>
<tr>
<td></td>
<td>1.61 (1.05-2.47)</td>
</tr>
<tr>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>rs1420101</td>
<td>G/A</td>
</tr>
<tr>
<td></td>
<td>2.89 (1.18-3.03)</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>rs1946131</td>
<td>G/A</td>
</tr>
<tr>
<td></td>
<td>1.47 (0.91-2.68)</td>
</tr>
<tr>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>rs1921622</td>
<td>G/A</td>
</tr>
<tr>
<td></td>
<td>1.89 (1.18-3.03)</td>
</tr>
<tr>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>rs10204137</td>
<td>G/A</td>
</tr>
<tr>
<td></td>
<td>1.37 (0.87-2.16)</td>
</tr>
<tr>
<td></td>
<td>0.18</td>
</tr>
</tbody>
</table>

*OR = odds ratio, CI = confidence interval, P = p-value, P† = p-value adjusted for multiple comparisons.*
### B. OCS use

<table>
<thead>
<tr>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACMAN (n=720)</td>
<td>GALA II (n=876)</td>
<td>SAGE (n=525)</td>
<td>SLOVENIA (n=187)</td>
<td>ESTATe (n=104)</td>
<td>Meta-analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.70 (1.08-6.79)</td>
<td>0.03</td>
<td>0.09</td>
<td>1.25 (0.87-1.79)</td>
<td>0.23</td>
<td>0.65</td>
<td>0.93 (0.68-1.27)</td>
<td>0.65</td>
<td>0.70</td>
<td>1.60 (0.57-4.47)</td>
<td>0.36</td>
<td>0.90</td>
<td>1.15 (0.46-2.85)</td>
<td>0.77</td>
<td>0.77</td>
</tr>
<tr>
<td>1.52 (0.86-2.66)</td>
<td>0.15</td>
<td>0.27</td>
<td>1.32 (0.88-1.98)</td>
<td>0.18</td>
<td>0.27</td>
<td>1.10 (0.86-1.40)</td>
<td>0.49</td>
<td>0.65</td>
<td>0.78 (0.57-1.05)</td>
<td>0.09</td>
<td>0.20</td>
<td>0.95 (0.49-1.85)</td>
<td>0.89</td>
<td>0.90</td>
</tr>
<tr>
<td>1.08 (0.57-2.02)</td>
<td>0.83</td>
<td>0.83</td>
<td>1.20 (0.78-1.86)</td>
<td>0.41</td>
<td>0.49</td>
<td>1.10 (0.88-1.38)</td>
<td>0.44</td>
<td>0.65</td>
<td>0.76 (0.54-1.08)</td>
<td>0.10</td>
<td>0.10</td>
<td>0.81 (0.41-1.59)</td>
<td>0.54</td>
<td>0.90</td>
</tr>
<tr>
<td>1.69 (1.05-2.73)</td>
<td>0.03</td>
<td>0.09</td>
<td>1.03 (0.81-1.32)</td>
<td>0.80</td>
<td>0.80</td>
<td>0.94 (0.69-1.28)</td>
<td>0.70</td>
<td>0.70</td>
<td>1.04 (0.52-2.05)</td>
<td>0.90</td>
<td>0.90</td>
<td>1.15 (0.58-2.27)</td>
<td>0.70</td>
<td>0.70</td>
</tr>
</tbody>
</table>

### C. Any exacerbation

<table>
<thead>
<tr>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
<th>OR (95% CI)</th>
<th>P</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACMAN (n=720)</td>
<td>GALA II (n=876)</td>
<td>SAGE (n=525)</td>
<td>SLOVENIA (n=187)</td>
<td>ESTATe (n=104)</td>
<td>Meta-analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.63 (1.33-5.18)</td>
<td>0.006</td>
<td>0.03</td>
<td>1.63 (1.14-2.32)</td>
<td>0.009</td>
<td>0.01</td>
<td>1.04 (0.78-1.39)</td>
<td>0.80</td>
<td>0.80</td>
<td>1.19 (0.66-2.12)</td>
<td>0.73</td>
<td>0.83</td>
<td>1.09 (0.47-2.56)</td>
<td>0.83</td>
<td>0.86</td>
</tr>
<tr>
<td>1.28 (0.84-1.96)</td>
<td>0.26</td>
<td>0.26</td>
<td>1.52 (1.06-2.13)</td>
<td>0.01</td>
<td>0.03</td>
<td>1.35 (1.06-1.72)</td>
<td>0.01</td>
<td>0.01</td>
<td>0.83 (0.63-1.10)</td>
<td>0.18</td>
<td>0.36</td>
<td>1.05 (0.65-1.67)</td>
<td>0.83</td>
<td>0.83</td>
</tr>
<tr>
<td>1.37 (0.83-2.25)</td>
<td>0.22</td>
<td>0.26</td>
<td>1.45 (1.03-2.04)</td>
<td>0.03</td>
<td>0.04</td>
<td>1.35 (1.08-1.70)</td>
<td>0.009</td>
<td>0.01</td>
<td>0.67 (0.50-0.90)</td>
<td>0.009</td>
<td>0.03</td>
<td>0.84 (0.52-1.35)</td>
<td>0.47</td>
<td>0.83</td>
</tr>
<tr>
<td>1.52 (1.05-2.18)</td>
<td>0.02</td>
<td>0.04</td>
<td>1.29 (1.00-1.66)</td>
<td>0.04</td>
<td>0.04</td>
<td>0.91 (0.68-1.21)</td>
<td>0.50</td>
<td>0.66</td>
<td>0.81 (0.50-1.30)</td>
<td>0.38</td>
<td>0.83</td>
<td>0.95 (0.53-1.70)</td>
<td>0.86</td>
<td>0.86</td>
</tr>
</tbody>
</table>
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; ER, Emergency room; OCS, oral corticosteroid

Bold faced results are FDR corrected significant results (P<0.05). Missing values means the SNP was not present in the study.

* R = reference allele, E = effect allele.
†FDR corrected P value
‡ rs13431828 was not present in ESTATe, rs3771180 was used as a surrogate marker (LD $r^2 = 1$).
§ rs10204137 was not present in ESTATe, rs4988956 was used as a surrogate marker (LD $r^2 = 1$)
### Study population vs OR (95% CI)

<table>
<thead>
<tr>
<th>Study Population</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PACMAN</td>
<td>2.63 [1.33, 5.18]</td>
</tr>
<tr>
<td>GALA II</td>
<td>1.62 [1.14, 2.32]</td>
</tr>
<tr>
<td>SAGE</td>
<td>1.04 [0.78, 1.39]</td>
</tr>
<tr>
<td>SLOVENIA</td>
<td>1.19 [0.66, 2.12]</td>
</tr>
<tr>
<td>ESTATE</td>
<td>1.09 [0.47, 2.56]</td>
</tr>
</tbody>
</table>

**Meta-analysis**

1.31 [1.07, 1.59]

*Less 'any exacerbation' vs More 'any exacerbation'*

*Observed outcome for rs13431828 (C)*

---

This article is protected by copyright. All rights reserved.